EP
KYNB

Elkhorn Partners’s Kyntra Bio KYNB Stock Holding History

Elkhorn Partners’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-192
Closed -$258K – 36
2017
Q3 		$258K Sell
192
-140
-42% -$148K 0.17% 28
2017
Q2 		$268K Sell
332
-292
-47% -$203K 0.17% 31
2017
Q1 		$385K Sell
624
-76
-11% -$46.3K 0.22% 26
2016
Q4 		$375K Sell
700
-44
-6% -$22K 0.23% 28
2016
Q3 		$385K Sell
744
-56
-7% -$26.4K 0.23% 28
2016
Q2 		$328K Buy
800
+76
+10% +$34.8K 0.21% 31
2016
Q1 		$385K Sell
724
-4
-0.5% -$1.99K 0.24% 26
2015
Q4 		$555K Sell
728
-152
-17% -$101K 0.33% 25
2015
Q3 		$482K Hold
880
– – 0.3% 28
2015
Q2 		$517K Hold
880
– – 0.31% 24
2015
Q1 		$690K Hold
880
– – 0.39% 23
2014
Q4 		$601K Buy
+880
New +$566K 0.35% 25

Other funds holding KYNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Elkhorn Partners's KYNB Position: Q4 2017 in Review

Elkhorn Partners sold out of Kyntra Bio (KYNB) in Q4 2017, closing a stake of 192 shares — an estimated $258K sold.

Elkhorn Partners first reported a position in KYNB in Q4 2014 and held it in 12 quarters. The position peaked at $690K in Q1 2015. 187 funds tracked by Wall St. Rank hold KYNB as of Q4 2017.

  • Elkhorn Partners reported no remaining Kyntra Bio position as of Q4 2017 after selling out during the quarter.
  • Elkhorn Partners sold 192 Kyntra Bio shares in Q4 2017, an estimated $258K.
  • Elkhorn Partners first reported a position in Kyntra Bio in Q4 2014 and held it in 12 quarters.
  • Elkhorn Partners's Kyntra Bio position peaked at $690K in Q1 2015.
  • 187 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2017.

Based on Elkhorn Partners's 13F filing for Q4 2017, filed 14 Feb 2018.